We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Hemogenyx Pharmaceuticals Plc | LSE:HEMO | London | Ordinary Share | GB00BYX3WZ24 | ORD GBP0.01 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.065 | 4.10% | 1.65 | 1.622 | 1.678 | 1.68 | 1.622 | 1.65 | 1,887,786 | 16:35:10 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Finance Services | 0 | -3.98M | -0.0035 | -4.63 | 18.5M |
Date | Subject | Author | Discuss |
---|---|---|---|
09/1/2023 12:48 | Using the Company's expertise in developing cell therapies for cancer, it developed an approach that can be used to bring cell therapy approaches to another unmet need, the treatment of major existing and emerging viral infections, including SARS-CoV-2 | the chairman elect | |
09/1/2023 12:47 | The Directors believe that this significant discovery of a single target protein for use against multiple dangerous viruses is further evidence of the potential power of the Company's CBR technology, and demonstrates the possibility of accelerating the development of antiviral therapeutics as well as preventing epidemics and pandemics that could be caused by a multitude of pathogens. | the chairman elect | |
09/1/2023 12:45 | Single CBR Can Treat Multiple Viruses Hemogenyx Pharmaceuticals plc (LSE: HEMO) announces that it has made significant progress towards the practical use of its Chimeric Bait Receptor ("CBR") platform technology, designed to program immune cells to eliminate viral infections by destroying the viruses that cause them. The Company's scientists have identified a target protein that can be incorporated into a single multipurpose CBR-based therapeutic capable of treating multiple viruses that belong to different viral families, instead of having to make a separate CBR construct for every virus. Among them are Dengue, Ebola, Marburg, Zika and Chikungunya. These viruses are among the most dangerous to humans, causing serious and often fatal diseases, and for which few effective treatment options exist. | the chairman elect | |
09/1/2023 12:43 | This site is infested with vermin TROLLs all of whom require culling ASAP | the chairman elect | |
09/1/2023 12:41 | Yes just as with all the TROLLs | the chairman elect | |
09/1/2023 12:39 | You sound bitter 'truth'.Same rant on pyc. | lean5gb | |
09/1/2023 12:35 | Yes the premium placement with the super major US player no doubt! | the chairman elect | |
09/1/2023 12:33 | Certainly a placing coming at 16p. | bigalan3 | |
09/1/2023 12:14 | Massive LOLs @ all the desperate de-rampers | the chairman elect | |
09/1/2023 12:13 | Placing is going to be big discount | truthcaller | |
09/1/2023 12:03 | LOL - refer the latest TROLL to POST 8265 | the chairman elect | |
09/1/2023 12:02 | Placing soon | ridingthewaves1 | |
09/1/2023 11:48 | New intra day highs | the chairman elect | |
09/1/2023 11:42 | But I doubt it as I have not had one and my post 8265 explains the most likely reason why not!!!! | the chairman elect | |
09/1/2023 11:40 | If you have had one you should NOT be posting as it id against the law! | the chairman elect | |
09/1/2023 11:36 | Yes we all know what a market sounding is so what is your point? | the chairman elect | |
09/1/2023 11:32 | *market sounding... if you know you know | epifanio1 | |
09/1/2023 11:28 | If the market whispers of a JV with a super major US player [additionally will make a strategic investment at a premium] comes to pass then HEMO will almost certainly be trading north of 10p | the chairman elect | |
09/1/2023 11:22 | HEMO heading higher on very decent volumes.... | the chairman elect | |
09/1/2023 10:33 | badger609 Jan '23 - 10:31 - 8259 of 8260 (Filtered) | the chairman elect |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions